MONTREAL, Feb. 13,
2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB:
VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a
Canadian pharmaceutical company, today announced that Messrs.
Robert Raich and Charles Bisaillon have joined the Company's
Board of Directors and that Messrs. Michel
Trudeau, Stuart Fowler,
Didier Leconte and Ms. Tamara Close have all resigned from its Board of
Directors.
"We are pleased to welcome Robert and Charles to the Valeo Board
of Directors. They both bring many years of entrepreneurial spirit
and experience, and we look forward to benefit from their valuable
insight and perspective", said Richard
MacKay, Chairman. "We would also like to thank Michel,
Stuart, Didier and Tamara for their contribution and guidance to
our Board of Directors".
More about Robert Raich
Prior to establishing RaichLegal Inc, Robert Raich was a senior partner at Spiegel
Sohmer Inc., a Montreal firm
specializing in taxation law, where he served as managing partner
for over 25 years.
His areas of expertise include taxation advice for real estate
transactions, advice to both purchasers and vendors in acquisitions
and sales of businesses, corporate reorganizations, venture
capital financing and charitable planning.
Mr. Raich graduated from McGill
University and was called to the Barreau du Quebec in 1976. He has been recognized on
several occasions as one of the Best Lawyers in Canada in the fields of Taxation law and Law
of Estates and Trusts in Canada
and has been a frequent guest lecturer at McGill University Faculty of Law and tax
conferences.
More about Charles Bisaillon
Charles Bisaillon is an
entrepreneurial-minded leader who loves rapidly scaling
organizations in both wholesale & direct-to-consumer channels.
Charles is currently President and owner of Airtek Ltée, a leading
Canadian manufacturing company, established in Montreal Quebec since 1970. Charles is also
the Chief Financial Officer Groupe J.B a residential, commercial
& institutional construction company.
Mr. Bisaillon graduated from l'École des sciences de la gestion,
UQAM. He is a chartered professional accountant of Canada (CPA Canada).
About Valeo Pharma Inc.
Valeo Pharma is a Canadian pharmaceutical company dedicated to
the commercialization of innovative prescription products in
Canada with a focus on
Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Headquartered in Kirkland, Quebec
Valeo Pharma has all the required capabilities and the full
infrastructure to register and properly manage its growing product
portfolio through all stages of commercialization. For more
information, please visit www.valeopharma.com and follow us on
LinkedIn and Twitter.
Forward Looking
Statements
Forward-looking statements are statements and information
regarding possible events, conditions or results of operations that
are based upon assumptions about future economic conditions and
courses of action. All statements and information other than
statements of historical fact may be forward-looking statements. In
some cases, forward-looking statements can be identified by the use
of words such as "seek", "expect", "anticipate", "budget", "plan",
"estimate", "continue", "forecast", "intend", "believe", "predict",
"potential", "target", "may", "could", "would", "might", "will" and
similar words or phrases (including negative variations) suggesting
future outcomes or statements regarding an outlook.
Forward-looking information is subject to known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from those expressed or implied
by such forward-looking information, including but not limited to:
reliance on third-party suppliers and manufacturers, the
availability of additional funding, common risks for pharmaceutical
products, including product liability claims, insurance and
recalls, registration risks in certain jurisdictions, the inability
to implement Valeo's strategy to grow the business, dependence on
key management personnel and executives, competition, currency
fluctuations and the risks, uncertainties and other factors
contained in the section entitled "Risk Factors" in Valeo's annual
information form dated January 29,
2024, a copy of which is available on Valeo's Sedar+ profile
at www.sedarplus.ca.
Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown
risks affect Valeo's business, or if Valeo's estimates or
assumptions turn out to be inaccurate. Valeo undertakes no
obligation to update publicly, or otherwise revise, any
forward-looking statements, whether as a result of new information
or future events or otherwise, except as may be required by law. If
Valeo does update one or more forward-looking statements, no
inference should be drawn that it will make additional updates with
respect to those or other forward-looking statements, unless
required by law.
SOURCE Valeo Pharma Inc.